BGMNasdaqPharmaceutical PreparationsFiscal year ends September 30
BGM Group Ltd.
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jul 21, 2026
$8.97+0.32 (+3.70%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Gross margin
16.6%+1.6 pts over 5 years
Operating margin
-33.2%−42.8 pts over 5 years
Net margin
-52.6%−62.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +51.1% | -16.4% | -5.4% | – | |
| Gross profit | +53.4% | +0.4% | -3.5% | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 22.0% | -9.2% | |
| Return on assets | – | 12.1% | -8.2% | |
| Current ratio | – | 2.04 | 1.24 | |
| Interest coverage | – | 19.8× | – | |
| Inventory turnover | – | 3.5× | 2.5× | |
| Capex to revenue | – | 0.9% | 4.1% | |
| Diluted shares | – | 6M | 113M |
Where the cash went
Fiscal 2021 to 2025, five years combined
BGM generated $16.23M from operations and spent $7.30M on capital expenditure, dividends and share buybacks. 76% of that went back into the business.
Generated
$16.23M
Used
$7.30M
Capital expenditure$5.51M76%Dividends$1.79M24%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-52.6%
×Asset turnover0.16×
×Equity multiplier1.12×
=Return on equity, FY2025-9.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -52.6% | 0.16× | 1.12× | -9.2% |
| FY2024 | -5.7% | 0.48× | 1.22× | -3.4% |
| FY2023 | -16.7% | 0.80× | 1.21× | -16.2% |
| FY2022 | 1.7% | 0.93× | 1.30× | 2.0% |
| FY2021 | 5.5% | 0.92× | 1.53× | 7.8% |
| FY2020 | 10.1% | 1.20× | 1.81× | 22.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$19.94M
- Cash generatingOperating cash flow above zero-$2.37M
- Return on assets improvedROA up on the prior year-2.8% → -37.6%
- Earnings backed by cashOperating cash flow above net income-$2.37M vs -$19.94M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.39 → 1.24
- No dilutionShare count did not rise7M → 113M
- Gross margin improvedGross margin up on the prior year16.39% → 16.64%
- More efficientAsset turnover rose0.49 → 0.72